Washington University Patent for Toxoplasma Gondii Treatment Compounds

The USPTO granted Patent US12600727B2 to Washington University for compounds useful in treating infections caused by Toxoplasma gondii and closely related parasites. The patent covers the compounds themselves, their pharmaceutically acceptable salts, pharmaceutical compositions including veterinary compositions, and methods of treatment and/or prophylaxis. The patent was filed on September 18, 2019, under CPC classifications C07D 487/04, A61P 33/10, and A61K 31/505.

For affected parties in the pharmaceutical and biotechnology sectors, this patent grant establishes intellectual property protection that may influence research directions, partnership opportunities, and licensing negotiations related to antiparasitic drug development. Companies developing competing treatments for T. gondii infections should assess potential infringement risks and freedom-to-operate considerations.